The immunoinhibitory B7-H1 molecule as a potential target in cancer: killing many birds with one stone.

ABSTRACT

Over expression of B7-H1 (also named PDL-1 or CD 274) molecule in cancer has been linked to worse prognosis and resistance to anti-cancer therapies in several malignancies. In this review, we update on the expression of B7-H1 molecule in solid and hematological malignancies. We also describe the possible mechanisms by which this molecule inhibits/downregulates the immune response to cancer cells. Finally, we highlight current and future potential therapeutic strategies that can be further developed to target this molecule.